Publications by authors named "Paul D Lyne"

Claim this Profile
D
Discovery of (2)--[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor.
Qibin Su, Erica Banks, Geraldine Bebernitz, Kirsten Bell, Cassandra F Borenstein, Paul D Lyne

J Med Chem· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors.
Garrett W Rhyasen, Yi Yao, Jingwen Zhang, Austin Dulak, Lillian Castriotta, Paul D Lyne

PLoS One· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological Inhibition of PARP6 Triggers Multipolar Spindle Formation and Elicits Therapeutic Effects in Breast Cancer.
Zebin Wang, Shaun E Grosskurth, Tony Cheung, Philip Petteruti, Jingwen Zhang, Paul D Lyne

Cancer Res· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
Lakshmaiah Gingipalli, Michael H Block, Larry Bao, Emma Cooke, Les A Dakin, Paul D Lyne

Bioorg Med Chem Lett· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adventures in Scaffold Morphing: Discovery of Fused Ring Heterocyclic Checkpoint Kinase 1 (CHK1) Inhibitors.
Bin Yang, Melissa M Vasbinder, Alexander W Hird, Qibin Su, Haixia Wang, Paul D Lyne

J Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Sarah J Ross, Alexey S Revenko, Lyndsey L Hanson, Rebecca Ellston, Anna Staniszewska, Paul D Lyne

Sci Transl Med· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering.
Chungang Gu, Michelle L Lamb, Jeffrey W Johannes, Mark A Sylvester, Mark S Eisman, Paul D Lyne

Bioorg Med Chem Lett· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo.
James E Dowling, Marat Alimzhanov, Larry Bao, Claudio Chuaqui, Christopher R Denz, Paul D Lyne

ACS Med Chem Lett· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering.
Jeffrey W Johannes, Lynsie Almeida, Kevin Daly, Andrew D Ferguson, Shaun E Grosskurth, Paul D Lyne

Bioorg Med Chem Lett· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia.
Erika K Keeton, Kristen McEachern, Keith S Dillman, Sangeetha Palakurthi, Yichen Cao, Paul D Lyne

Blood· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.
James E Dowling, Marat Alimzhanov, Larry Bao, Michael H Block, Claudio Chuaqui, Paul D Lyne

ACS Med Chem Lett· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Disubstituted Imidazo[4,5-b]pyridines and Purines as Potent TrkA Inhibitors.
Tao Wang, Michelle L Lamb, Michael H Block, Audrey Molina Davies, Yongxin Han, Paul D Lyne

ACS Med Chem Lett· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases.
Les A Dakin, Michael H Block, Huawei Chen, Erin Code, James E Dowling, Paul D Lyne

Bioorg Med Chem Lett· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization.
James E Dowling, Claudio Chuaqui, Timothy W Pontz, Paul D Lyne, Nicholas A Larsen

ACS Med Chem Lett· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of amidoheteroaryls as potent inhibitors of mutant (V600E) B-Raf kinase with in vivo activity.
Paul D Lyne, Brian Aquila, Donald J Cook, Les A Dakin, Jay Ezhuthachan

Bioorg Med Chem Lett· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer.
David A Scott, Brian M Aquila, Geraldine A Bebernitz, Donald J Cook, Les A Dakin, Paul D Lyne

Bioorg Med Chem Lett· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of 4-aminopyrazolylpyrimidines as potent inhibitors of Trk kinases.
Tao Wang, Michelle L Lamb, David A Scott, Haixia Wang, Michael H Block, Paul D Lyne

J Med Chem· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring.
Paul D Lyne, Michelle L Lamb, Jamal C Saeh

J Med Chem· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lead hopping using SVM and 3D pharmacophore fingerprints.
Jamal C Saeh, Paul D Lyne, Bryan K Takasaki, David A Cosgrove

J Chem Inf Model· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
On evaluating molecular-docking methods for pose prediction and enrichment factors.
Hongming Chen, Paul D Lyne, Fabrizio Giordanetto, Timothy Lovell, Jin Li

J Chem Inf Model· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of compounds with nanomolar binding affinity for checkpoint kinase-1 using knowledge-based virtual screening.
Paul D Lyne, Peter W Kenny, David A Cosgrove, Chun Deng, Sonya Zabludoff

J Med Chem· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based virtual screening: an overview.
Paul D Lyne

Drug Discov Today· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis